pHLA-targeting Biotherapeutics
Oncology (unspecified cancers)
Key Facts
About BioCopy
BioCopy is a private, pre-clinical stage biotech leveraging a proprietary AI-powered platform named ValidaTe to unlock the challenging target space of intracellular peptide-HLA (pHLA) complexes. Its focus is on developing novel biotherapeutics that act as matchmakers to guide immune cells precisely to cancer cells, aiming to overcome the limitations of current therapies in terms of specificity, safety, and development speed. The company operates as a platform/therapeutics hybrid, targeting significant bottlenecks in oncology drug discovery and positioning itself as a potential partner for larger pharmaceutical companies. While still in the research and development phase, its technology addresses a high-value, underserved area in immuno-oncology.
View full company profileTherapeutic Areas
Other Oncology (unspecified cancers) Drugs
| Drug | Company | Phase |
|---|---|---|
| Pan-KRAS Inhibitor Programs | BlossomHill Therapeutics | Pre-clinical |
| Microcystin-based ADC Payload | Simris Biologics | Pre-clinical |
| In vivo CAR-T programs | Interius BioTherapeutics | Pre-clinical |